Zealand Pharma's restructuring plan has led to dismissals in Denmark
Last week’s announcement that Zealand Pharma was planning to scale down its operations in the US by 90 percent has had a wider impact than first assumed – CEO Adam Steensberg now tells MedWatch that Danish staffing has also been reduced.
by christopher due karlsson, translated by daniel pedersen
More than just Zealand Pharma’s employees in the US are bearing the brunt of the company’s streamlining plans. Danish staffing has also suffered a blow, says the newly appointed CEO, Adam Steensberg, to MedWatch.